secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-08-21T12:01:10+00:00
Accession:  0001728117-26-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio raises $25M initial private placement, up to $225M more tied to FDA milestones
--------------------------------------------------------------------------------

- Initial closing expected Aug 24, 2026: ~$25M gross from pre-funded warrants at $0.1399/share.
- Second closing of ~$125M upon FDA acceptance of NDA for seralutinib in PAH; FDA Approval Warrants add ~$100M.
- Proceeds to fund clinical development and commercialization of seralutinib in PAH and PH-ILD.
- Warrants exercisable for preferred stock pre-stockholder approval, then common stock; conversion prices $0.14 and $0.187.
- Company lock-up until FDA approval warrants exercised or Dec 31, 2026 if second closing not met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/0001728117-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/goss-20260820.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer